![]() |
市場調査レポート
商品コード
1684127
メディカルアフェアーズ(2030年) - 戦略的進化Medical Affairs 2030 - Charting the Strategic Evolution |
||||||
|
メディカルアフェアーズ(2030年) - 戦略的進化 |
出版日: 2025年01月28日
発行: FirstWord Group
ページ情報: 英文
納期: 即日から翌営業日
|
メディカルアフェアーズは、2030年までに製薬業界の礎となるべく、変革的な進化を遂げようとしています。
メディカルアフェアーズは、研究開発チームやコマーシャルチームとともに、サポート機能から戦略的リーダーシップの役割へと移行し、AIやテレヘルスのようなデジタル技術の統合によって進化を遂げます。さらに、メディカルアフェアーズは患者中心の戦略を重視し、患者の声を代弁して治療が患者のニーズを満たすようにします。
当レポートでは、メディカルアフェアーズコンサルタントであり、MSL(Medical Science Liaison)のCEOであるSamuel Dyer氏に話を聞きました。メディカルサイエンスリエゾン(MSL)協会に、メディカルアフェアーズの進化における患者中心のアプローチとRWEの役割について聞き、その内容をまとめています。
Medical affairs is poised for a transformative evolution by 2030, becoming a cornerstone of the pharmaceutical industry.
Transitioning from a support function to a strategic leadership role alongside R&D and commercial teams, medical affairs' evolution is driven by the integration of digital technologies like AI and telehealth. Furthermore, medical affairs will focus on patient-centric strategies, representing patient voices to ensure treatments meet their needs.
FirstWord spoke to Samuel Dyer, medical affairs consultant and CEO of the Medical Science Liaison (MSL) Society, about the role of patient-centric approaches and RWE in the evolution of medical affairs.
Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.